The International Journal of Neuropsychopharmacology
May 5, 2026
Hiroyuki Uchida, Gabriella Gobbi, Joseph Zohar et al.
BACKGROUND: Over the past decade, neuropsychopharmacology has shifted from stagnation to momentum, with first-in-class mechanisms and biomarker-enabled trials spanning psychiatry and neurology. METHODS: We narratively synthesized advances from 2013 to 2026 across central nervous system (CNS) discovery and development, including pivotal trials, regulatory actions, digital/real-world evidence,...
The International Journal of Neuropsychopharmacology
August 1, 2025
Andrew S. Gibbons, Paul Liknaitzky, Suresh Sundram
Abstract Background Early intervention and management of Generalised Anxiety Disorder (GAD) is essential to effectively reduce both symptom severity and the risk of developing other psychiatric disorders. However, current first-line treatments are only about 50% effective, with high rates of relapse and many adverse effects. Psychedelic medicines, such as psilocybin, have emerged as promising...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
May 15, 2025
Chitra Vinnakota, Matthew R Hudson, Kazutaka Ikeda et al.
6 citations
Working memory relies on synchronised network oscillations involving complex interplay between pyramidal cells and GABAergic interneurons. NMDA receptor (NMDAR) antagonists influence both network oscillations and working memory, but the relationship between these two consequences has not been elucidated. This study aimed to determine the effect of NMDAR antagonists on network oscillations...
bioRxiv (Cold Spring Harbor Laboratory)
March 11, 2025
Devon Stoliker, Leonardo Novelli, Moein Khajehnejad et al.
8 citations
preprint
Abstract Psychedelics can profoundly alter consciousness by reorganising brain connectivity; however, their effects are contextsensitive. To understand how this reorganisation depends on the context, we collected and comprehensively analysed the largest psychedelic neuroimaging dataset to date. Sixty-two adults were scanned with functional MRI and EEG during rest and naturalistic stimuli...
Journal of Neuroscience Research
2024
Chitra Vinnakota, Anna Schroeder, Xin Du et al.
7 citations
Noncompetitive NMDA receptor (NMDAR) antagonists like phencyclidine (PCP) and ketamine cause psychosis-like symptoms in healthy humans, exacerbate schizophrenia symptoms in people with the disorder, and disrupt a range of schizophrenia-relevant behaviors in rodents, including hyperlocomotion. This is negated in mice lacking the GluN2D subunit of the NMDAR, suggesting the GluN2D subunit mediates...
Schizophrenia Bulletin
December 7, 2020
Ilvana Dzafic, Kit Melissa Larsen, Hayley Darke et al.
26 citations
Recent theories in computational psychiatry propose that unusual perceptual experiences and delusional beliefs may emerge as a consequence of aberrant inference and disruptions in sensory learning. The current study investigates these theories and examines the alterations that are specific to schizophrenia spectrum disorders vs those that occur as psychotic phenomena intensify, regardless of...